Clinical Research Directory
Browse clinical research sites, groups, and studies.
FIA Acute Inflammation
Sponsor: University of Zurich
Summary
The goal of this clinical trial is to learn how acute inflammation affects the body's ability to absorb iron in adults who are hospitalized with community-acquired pneumonia. The main questions it aims to answer are: * How does intestinal iron absorption change during acute inflammation compared with after recovery? * How are changes in iron absorption related to markers of iron metabolism and inflammation, including hepcidin? Participants will: * Receive an oral dose of stable isotope-labelled ⁵⁷Fe-ferrous sulfate, followed one hour later by a small intravenous dose of stable isotope-labelled ⁵⁸Fe-citrate. * Provide blood samples to measure iron absorption, iron status, and markers of inflammation. * Repeat the study procedures after recovery from the acute illness to compare iron absorption during acute inflammation and convalescence. * Attend follow-up visits over approximately 3-4 months.
Official title: Fractional Iron Absorption in Acute Inflammation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2026-11-09
Completion Date
2029-11
Last Updated
2026-11-12
Healthy Volunteers
No
Conditions
Interventions
⁵⁷Fe-labelled ferrous sulphate
Single oral dose of 10 mg elemental iron as stable isotope-labelled ⁵⁷Fe-ferrous sulfate, administered under supervision with 200 mL water and a standardised test meal (white bread, butter, honey) after a fast of at least 4 hours; fasting continues for 4 hours after dosing. Administered twice per participant: once during the acute inflammatory phase (Visit 1, within 72 hours of hospitalization, CRP \>=100 mg/L) and once during convalescence (Visit 3, 3-8 weeks after hospital discharge, CRP \<=10 mg/L). The oral tracer serves as the test dose for quantification of fractional intestinal iron absorption.
⁵⁸Fe-citrate
Single intravenous reference dose of 100 µg total iron as stable isotope-labelled ⁵⁸Fe-citrate, diluted in 100 mL 0.9% sodium chloride and infused over 50 minutes by infusion pump through a peripheral venous catheter, starting 1 hour after the oral ⁵⁷Fe dose, with monitoring during and after the infusion. Administered twice per participant, at Visit 1 (acute inflammatory phase) and Visit 3 (convalescent phase). Because the intravenous tracer bypasses the intestine, it serves as the reference tracer for calculating fractional iron absorption from erythrocyte incorporation of the oral relative to the intravenous isotope.
Locations (1)
Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich
Zurich, Canton of Zurich, Switzerland